Proactive Investors - Run By Investors For Investors

Sareum submits cancer trial application

The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum.
Sareum submits cancer trial application
Two clinical trials in cancer patients are planned.

Drug developer Sareum (LON:SAR) has submitted its application for two Phase I clinical trials of CHK1 inhibitor CCT245737  to the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum. 

Two clinical trials in cancer patients are planned. One will use CCT245737 as a single anti-cancer agent and the other in combination with standard-of-care chemotherapy.

Once approval is obtained, these trials will be funded in collaboration with co-development partner, the CRT Pioneer Fund.

Sareum has put up £797,500 of development funding so far.

Tim Mitchell, chief executive, said it was a further significant step towards the planned clinical trials with cancer patients.

Checkpoint Kinase 1 (CHK1)  helps control the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage. 

Why Invest In Sareum Holdings Plc? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile

Sareum Holdings Plc Timeline

May 17 2016
March 24 2016
October 26 2015

Related Articles

September 10 2015
VolitionRx’s tests are based on the science of Nucleosomics, which identifies and measures nucleosomes in the bloodstream.
January 20 2016
“Redx Pharma’s in-licensed and internally generated pipeline of proprietary drug candidates targeting significant unmet medical needs, particularly in the fields of infection and oncology, offers unique exposure to a number of exciting early-stage opportunities, in our view,” said Shore Capital analyst Dr Tara Raveendran.
February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.